Opko Health Inc. (OQ:OPK)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd
MIAMI FL 33137-3212
Tel: 1-212-8383777
Website: www.opko.com
IR: See website
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Geoff Monk
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President
Jon Roger Cohen
Executive Chairman of BioReference Laboratories
Steven D. Rubin
Executive Vice President - Administration, Director
Business Overview
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Financial Overview
For the six months ended 30 June 2019, Opko Health Inc. revenues decreased 13% to $448.8M. Net loss increased from $49.3M to $140.6M. Revenues reflect Diagnostics segment decrease of 16% to $357.3M, United States segment decrease of 16% to $369.2M, Chile segment decrease of 29% to $16.9M, Spain segment decrease of 8% to $9.3M. Higher net loss reflects Diagnostics segment loss increase from $6.5M to $61.6M.
Employees: 5,690 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $1,519M as of Jun 30, 2019
Annual revenue (TTM): $920.49M as of Jun 30, 2019
EBITDA (TTM): -$123.42M as of Jun 30, 2019
Net annual income (TTM): -$244.29M as of Jun 30, 2019
Free cash flow (TTM): -$180.66M as of Jun 30, 2019
Net Debt Last Fiscal Year: $183.58M as of Jun 30, 2019
Shares outstanding: 615,601,045 as of Jul 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization